INR Scientific Publications

Selected INR Scientific Publications

• On Overcoming Barriers to Application of Neuroinflammation Research. Tobinick E, Ignatowski, T., Spengler, R. In: Abreu GEA, ed. Mechanisms of Neuroinflammation: InTechOpen; 2017.
• Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. CNS Drugs 2014, doi: 10.1007/s40263-014-0174-2.
• Immediate neurological recovery following perispinal etanercept years after brain injury. Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Clin Drug Investig. 2014 May;34(5):361-6.
• Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury – An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. Edward Tobinick MD, Nancy M. Kim MD, et.al. CNS Drugs. 2012 Dec;26(12):1051-70.
• Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Edward Tobinick M.D. Current Alzheimer Research. 2012 Jan;9(1):99-109.
• Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. Edward Tobinick MD. CNS Drugs. 2011 Feb;25(2):145-155.
• Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD.  Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
• Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
• The value of drug repositioning in the current pharmaceutical market. Edward Tobinick MD. Drug News Perspect. 2009 Mar;22(2):119-25. Review.
• Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. Edward Tobinick MD, K Chen PhD, X Chen PhD. BMC Res Notes. 2009 Feb 27;2:28.
• Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
• Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Edward Tobinick MD. Medscape J Med. 2008 Jun 10;10(6):135.
• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
• Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.Edward Tobinick MD. Neurology. 2008 Apr 1;70(14):1222-3.
• Perispinal etanercept for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
• A critique of intradiscal administration for treatment of radiculopathy. Edward Tobinick MD. Anesthesiology. 2008 Feb;108(2):334.
• Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
• Spinal delivery of p38: TNF-alpha inhibitors.PLoS Med. 2006 Nov;3(11):e511.
• TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, Hyman Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
• The cerebrospinal venous system: anatomy, physiology, and clinical implications. Edward Tobinick MD. MedGenMed. 2006 Feb 22;8(1):53.
• Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Edward Tobinick MD, Susan Davoodifar MD. Curr Med Res Opin. 2004 Jul;20(7):1075-85.
• Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Edward Tobinick MD. Clinical Therapeutics. 2003 Aug;25(8):2279-88.

• Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation. Spine (Phila Pa 1976), 2013. 38(23): p. 1986-94. Freeman, B.J., et. al.
• Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976), 2012. 37(6): p. 439-44. Ohtori, et. al.
• Therapeutic evaluation of etanercept in a model of traumatic brain injury.Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, Chang CP. J Neurochem. 2010 Nov;115(4):921-9.
• Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. Frankola KA, Greig NH, Luo W, Tweedie D. CNS Neurol Disord Drug Targets. 2011 Feb 2.
• Anti-TNF therapy in the injured spinal cord. Esposito E, Cuzzocrea S. Trends Pharmacol Sci. 2011 Feb;32(2):107-15. Epub 2010 Dec 23.
• Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Anesth Analg. 2011 Feb;112(2):454-9.
• Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J. Brain Res. 2011 Jan 12;1368:239-47.
• Attenuation of Inflammatory Events in Human Intervertebral Disc Cells with a Tumor Necrosis Factor Antagonist. Sinclair SM, Shamji MF, Chen J, Jing L, Richardson WJ, Brown CR, Fitch RD, Setton LA. Spine (Phila Pa 1976). 2011 Jan 6.
• Intrathecal inflammation precedes development of Alzheimer’s disease. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
• Perispinal etanercept: potential as an Alzheimer therapeutic.Griffin WS. J Neuroinflammation. 2008 Jan 10;5:3.
• Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Park KM, Bowers WJ. Cell Signal. 2010 Jul;22(7):977-83.
• The roles of TNF in brain dysfunction and disease. Clark IA, Alleva LM, Vissel B. Pharmacol Ther. 2010 Dec;128(3):519-48.
• An association study of 21 potential Alzheimer’s disease risk genes in a Finnish population. Sarajärvi T, Helisalmi S, Antikainen L, Mäkinen P, Koivisto AM, Herukka SK, Haapasalo A, Soininen H, Hiltunen M. J Alzheimers Dis. 2010;21(3):763-7.
• The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide.Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB. Behav Brain Res. 2010 May 1;209(1):165-73.
• Soluble TNF receptors are associated with A-beta metabolism and conversion to dementia in subjects with mild cognitive impairment. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Neurobiol Aging. 2010 Nov;31(11):1877-84.
• Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. McNaull BB, Todd S, McGuinness B, Passmore AP. Gerontology. 2010;56(1):3-14.
• Systemic inflammation and disease progression in Alzheimer disease. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Neurology. 2009 Sep 8;73(10):768-74.
• Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’. Wolinsky H. EMBO Rep. 2008 May;9(5):416-8.